This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH) (Biomarkers)

This study has been completed.
Information provided by:
Northwell Health Identifier:
First received: November 29, 2007
Last updated: June 22, 2011
Last verified: June 2011
The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic peptide (BNP) and MIF levels pre and post exercise.

Condition Intervention
Pulmonary Arterial Hypertension Other: Blood draw

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Biomarkers in the Diagnosis and Assessment of PAH

Resource links provided by NLM:

Further study details as provided by Northwell Health:

Primary Outcome Measures:
  • Assess the correlation of plasma/arterial BNP and MIF levels pre/post with the 6 Minute walk test distance and echocardiographic parameters as surrogate markers of severity of PAH. [ Time Frame: 2 year ]

Secondary Outcome Measures:
  • To determine if changes in plasma/arterial MIF levels pre/post 6MW test are due to MIF released from the lungs [ Time Frame: 2 year ]

Enrollment: 75
Study Start Date: May 2007
Study Completion Date: June 2010
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Patients with Pulmonary Arterial Hypertension
Other: Blood draw
Venous and Arterial Blood draw samples; 6 Minute Walk test

Detailed Description:
As above

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of PAH, based on currently accepted gold standard for Right Heart Catheterization.
  • Patients with mean artery pressure of greater that 25 mm Hg at rest or 30mm Hg during exercise with pulmonary capillary wedge pressure less than 18mm Hg on right heart catheterization.

Exclusion Criteria:

  • Significant left heart disease or renal insufficiency (serum creatinine > 1.5 mg%).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00566423

United States, New York
North Shore-Long Island Health System
New Hyde Park, New York, United States, 11040
Sponsors and Collaborators
Northwell Health
Principal Investigator: Arunabh Talwar, MD Northwell Health
  More Information

Responsible Party: Arunabh Talwar MD, North Shore-Long Island Jewish Health System Identifier: NCT00566423     History of Changes
Other Study ID Numbers: 07-030
NS-LIJHS IRB # 07-030
Study First Received: November 29, 2007
Last Updated: June 22, 2011

Keywords provided by Northwell Health:
6 Minute Walk (6MW)

Additional relevant MeSH terms:
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases processed this record on September 20, 2017